LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today provided an update on development plans of its flagship pathogen detection platform for the human clinical, veterinary diagnostics and food safety sectors. As previously announced, LexaGene has recently placed a pre-commercial unit of its “LX Analyzer” in a major U.S. hospital laboratory for the testing of COVID-19, as well as submitted its plan to the FDA for Emergency Use Authorization (“EUA”). “The analyzer’s multiplex testing capability is an important part of future testing needs, especially if the anticipated second wave of COVID-19 testing in the fall occurs with the added burden of a new flu season. The LX Analyzer is capable of testing for COVID-19, as well as flu and other common respiratory pathogens such as adenovirus and RSV at the point-of-need in clinics, hospitals, or elsewhere in the field,” Dr. Jack Regan, CEO and founder of LexaGene, stated in the news release. “Hospitals have told us what they need, and we are working with partners on the research of this deadly virus with the hope of being the testing provider they choose. We are pleased so far with the results of our current placement.”
To view the full press release, visit http://nnw.fm/uO7Vi
About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press “go.” The “LX Analyzer” delivers excellent sensitivity, specificity, and breadth of detection and can return results in about one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information, visit the company’s website at www.LexaGene.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork
